TNFRSF4 and neoplasm: In this report, we tested how tumor volume and tumor model influenced the anti-tumor efficacy and mechanism of the in-situ vaccine CpG + OX40 in two preclinical tumor types where clinical IT injections are clinically achievable due to tumor accessibility.